P485: The combined of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn’s diseaseECCO '16 Amsterdam
2016
P486: Intrapatient variability in adalimumab drug levels within and across cycles in Crohn’s diseaseECCO '16 Amsterdam
2016
P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisationECCO '16 Amsterdam
2016
P488: IBS-type symptoms in patients with quiescent inflammatory bowel disease are unrelated to ongoing inflammationECCO '16 Amsterdam
2016
P489: Predicting mucosal state with faecal calprotectin in children with Crohn’s disease.ECCO '16 Amsterdam
2016
P490: Clinicians’ adherence to European Crohn’s and Colitis Organisation guidelines in the clinical care of adults with inflammatory bowel diseaseECCO '16 Amsterdam
2016
P491: In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.ECCO '16 Amsterdam
2016
P492: Perioperative complications have long-term effect on quality of life after restorative proctocolectomyECCO '16 Amsterdam
2016
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s diseaseECCO '16 Amsterdam
2016
P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel diseaseECCO '16 Amsterdam
2016
P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experienceECCO '16 Amsterdam
2016
P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysisECCO '16 Amsterdam
2016
P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general populationECCO '16 Amsterdam
2016
P498: Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapyECCO '16 Amsterdam
2016
P499: Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from KoreaECCO '16 Amsterdam
2016
P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA studyECCO '16 Amsterdam
2016
P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulationECCO '16 Amsterdam
2016